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M. nemestrina immunized with an apathogenic HIV-2 molecular clone (HIV-2KR) were protected from CD4 decline and
disease upon challenge with HIV-2287, after any immunizing virus could be detected. Higher but not lower inocula of HIV-2KR
were protective against intravenous inoculation of either 105 or 101 TCID50 of HIV-2287. Protected animals displayed
substantial reductions in PBMC proviral burden (1–3 logs), viral titers (1–2 logs), and plasma viral RNA (2–4 logs) compared
to unprotected or naive animals as early as 1 week postinfection. Plasma viral RNA became undetectable after 24 weeks in
protected animals, but remained high in unprotected animals. No viral RNA was present in the spleen of the protected animal
necropsied more than a year after challenge (though viral DNA was still present). No neutralizing responses could be
demonstrated, but CTL activity was detected sooner and at higher levels after challenge in protected than in unprotected
macaques. In this novel HIV-2 vaccine model, protection was clearly dose-dependent, and clearance of challenge virus RNA
from the plasma did not require detectable ongoing replication of the immunizing virus at the time of challenge. © 1998
Academic Press
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INTRODUCTION
Live-virus vaccination strategies have demonstrated
that broad and persistent protection against SIV infection
can be achieved (Marthas et al., 1990; Daniel et al., 1992;
Lohman et al., 1994; Almond et al., 1995; Clements et al.,
1995; Putkonen et al., 1995, 1996; Hirsch et al., 1996;
Wyand et al., 1996). However, persistent replication of
immunizing virus over a significant period of time has
been found to be needed for induction of complete pro-
tection, as replication of challenge virus has been de-
tected when animals were challenged earlier after im-
munization (Wyand et al., 1996), though protection from
disease was still generally achieved. Results with poten-
tially safer, but generally less efficacious, strategies, in-
cluding subunit vaccines, DNA immunization, and inac-
tivated virus vaccines, have also illustrated that failure to
protect against infection did not imply failure to protect
against occurrence of disease in primate models (Mar-
thas et al., 1992; Hu et al., 1992a,b, 1993; Israel et al.,
1994; Lehner et al., 1996; Lu et al., 1996; Mossman et al.,
1996). Concerns about the safety of live-virus strategies
have been accentuated by the observation that attenu-
ated SIV virus was nonetheless capable of inducing
disease when administered to immunologically incom-
petent (newborn) macaques (Baba et al., 1995). Thus,
exploring less replicative immunizing viruses, which may
not be capable of producing complete protection against
infection, is an appropriate goal, if such an infection still
produces an immune state which leads to early control
of virus replication and prevents or delays the onset of
disease.
Recently, the HIV-2KR molecular clone has been shown
to produce only limited infection in M. nemestrina (Kraus
et al., 1998), characterized by transient detectable vire-
mia (2–24 weeks), and modest and temporary decline in
CD4 lymphocyte numbers. HIV-2KR represents a mini-
mally infectious and genetically uniform ‘‘immunizing’’
virus, suitable for exploring protection from virulent iso-
lates in a live-virus vaccination system. To determine the
nature and extent of protection induced by HIV-2KR infec-
tion, four animals, previously inoculated with higher [104
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150
SFU (syncytia-forming units)] or lower (103 SFU) doses of
HIV-2KR, were challenged, together with six naive ani-
mals, with either high (105 TCID50) or low (10
1 TCID50)
doses of HIV-2287, a highly pathogenic HIV-2 isolate (Ho
et al., 1996). Following challenge, kinetics of CD4 decline
and viral replication were carefully assessed. In order to
obtain a preliminary indication of the mechanism(s) in-
volved in protection, serological reactivity, neutralizing
activity, and cytotoxic lymphocyte activity were also mon-
itored.
Intravenous inoculation of HIV-2287 at either study
dose was found to produce prompt and profound decline
of CD4 lymphocytes and onset of immunodeficiency dis-
ease in all naive animals. Animals initially immunized
with a lower dose of HIV-2KR displayed slower decline of
CD4 levels, and animals immunized with a higher dose
were protected from CD4 decline and effectively cleared
virus from the plasma. Viral replication was found to
predict eventual outcome, as assessed by quantitative
viral culture, viral DNA PCR, and quantitative competitive
plasma RNA PCR. In contrast to previously described
models of HIV-2 and SIV live-virus immunization (Daniel
et al., 1992), in vitro immune correlates of protection were
not present prior to HIV-2287 challenge, as no neutralizing
or bulk CTL activity was detectable 14 months after
HIV-2KR immunization. However, gag-specific CTL activ-
ity was observed promptly after challenge in protected
animals, suggesting that an anamnestic response may
have been primed by exposure to HIV-2KR. This vaccine
model represents a novel system of live-virus immuniza-
tion and protection from pathogenic infection, employing
exclusively human immunodeficiency viruses for both
immunization and challenge in a readily available pri-
mate species (M. nemestrina). Findings in this prelimi-
nary study suggest that protection may be dose-depen-
dent and that substantially lower levels of replication by
a live-virus immunogen may be needed to induce pro-
tection from disease than previously demonstrated in SIV
live-virus vaccine models.
RESULTS
Protection from CD4 decline
Four animals previously immunized with 104 or 103
SFU of HIV-2KR, together with six naive animals, were
inoculated intravenously with either 105 or 101 TCID50 of
HIV-2287 (Table 1). By 8 weeks postinoculation (wpi), all
six naive animals and animals immunized with the lower
dose of HIV-2KR (404 and 407) manifested CD4 decline
(Fig. 1). By 16 wpi, their CD41 lymphocyte numbers
declined to below 1% of the preinoculation value. In
contrast, only a transient, modest decline in CD4 num-
bers was noted in animals immunized with 104 SFU
HIV-2KR (292 and 350), whose CD4
1 lymphocyte num-
bers rose by 26 wpi to levels not significantly different
from preinoculation levels (Fig. 1). Decline of CD4 lym-
phocyte numbers was more prompt in animals chal-
lenged with 105 TCID50 of HIV-2287 (compare 292 with
350 and 407 with 404, Fig. 1A, and 096 and 192 with 147
and 172 in Fig. 1B) and slower in animals immunized with
the lower dose of HIV-2KR than in naive animals (com-
pare 404 and 407 in Fig. 1A with animals in Fig. 1B). No
differences between groups of animals were noted in
CD8 lymphocyte numbers or total white blood cell count
(data not shown). Naive animals were euthanized 24
weeks after infection, when clinical symptoms of immu-
nodeficiency, principally fever and wasting, were ob-
served. Pneumocystis carinii pneumonia (PCP) was doc-
umented in one animal. While animals with a low dose
HIV-2KR (404 and 407) experienced eventual CD4 decline,
onset of clinical disease was delayed compared to naive
animals; however, their clinical condition required eutha-
nasia by 56 wpi. In contrast, animals immunized with the
higher dose of HIV-2KR (292 and 350) remained free of
symptoms of immunodeficiency. Animal 292 remains
alive and asymptomatic, and animal 350 died due to
intestinal obstruction at 76 wpi.
Viral replication kinetics
To determine if limitation of virus replication correlated
with protection from CD4 lymphocyte decline, quantita-
tive cultures of PBMC were performed, proviral DNA
was determined by quantitative PCR, and plasma viral
RNA was measured using an EIA QC–PCR specific
for HIV-2287. Virus was isolated from all animals after
HIV-2287 inoculation. As few as 100 PBMC were required
for reisolation at the peak of viremia (Fig. 2). Viral DNA
burden in PBMC was of comparable magnitude (Fig. 3).
At 2 wpi, proviral burden was dramatically lower in the
protected animal given high-dose HIV-2287 (292—10
1.3)
than in the naive (104.0 and 103.5 for 096 and 192, respec-
tively) or the unprotected (407—103.5) animals given the
same inoculum. In contrast, little difference was seen at
2 wpi in animals which received the low dose of HIV-2287.
TABLE 1
Animals Used in HIV-2287 Challenge Experiment
Animal
HIV-2KR
Inoculum
(SFU)
HIV-2287
Inoculum
(TCID50)
CD4 decline
after HIV-2287
Inoculation
Immunodeficiency
disease
J92096 None 105 Rapid Rapid
T92192 None 105 Rapid Rapid
F91368 None 105 Rapid Rapid
M91392 None 105 Rapid Rapid
F92147 None 101 Rapid Rapid
J92172 None 101 Rapid Rapid
J90292 104 105 None None
F90350 104 101 None None
F90407 103 105 Rapid Delayed
F90404 103 101 Rapid Delayed
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By 4 wpi, however, animal 350 displayed a lower proviral
burden (101.8) than did the naive (102.2 and 102.9 for 147
and 172, respectively) or the unprotected (404—105.2)
animals given low-dose HIV-2287. Over time, proviral bur-
den in all groups of animals appeared to approach a
common mean (;103).
Similar findings were noted early in the course of
plasma viremia. Among the group receiving 105 TCID50
HIV-2287, plasma RNA copy numbers were lower in the
protected (292—105.4 copies ml21) than in the naive
(108.2 and 108.3 copies ml21 for 096 and 192, respectively)
or unprotected (407—108.2 copies ml21) animals at 1 wpi
(Fig. 4). Peak viremia was delayed in the group receiving
101 TCID50 HIV-2287, but a reduction was still seen at 2
wpi in the protected animal (350—106.2 copies ml21),
compared to the naive (107.4 and 107.1 copies ml21 for 147
and 172, respectively) and unprotected (404—106.6 cop-
ies ml21) animals. In contrast to the gradual increase in
proviral burden in all animals, plasma viremia declined
and diverged progressively in protected and unprotected
animals. Among the high-dose HIV-2287 group, plasma
viremia was 2.3–4.4 logs lower in the protected animal
(292—103.4 copies ml21) than in naive (107.8 and 105.7
copies ml21 for 096 and 192) or unprotected (407—106.9
copies ml21) animals by 16 wpi. Differences in the low-
dose HIV-2287 group were also evident. Viremia in the
protected animal (350—102.4 copies ml21) was 1–3.4
logs lower than in the naive (147—105.8 and 172—103.4)
or unprotected (404—103.5) animals at 1 wpi, and it was
1.2 logs lower (350—104.2) than in the unprotected ani-
mal (404—105.4 copies ml21) at 16 wpi. Substantial de-
cline in plasma RNA in naive animals (147—104.5 and
172—103.2 copies ml21) at 16 wpi probably reflected
destruction of the producing cell population.
Note the discrepancy of late viremia in protected and
unprotected HIV-2KR experienced animals (Fig. 4B, 52
wpi), where plasma viral copies declined to the level of
undetectability (102.3 copies ml21) in protected animals,
yet remained high (107.9, 106.4 copies ml21) in unpro-
tected animals 404 and 407. Plasma viral RNA could not
be detected in animals 292 and 350 after 24 wpi (not
shown). Plasma viremia remained undetectable 22
months after HIV-2287 inoculation in animal 292, and
proviral DNA also declined to below 102 copies/106
PBMC (not shown). In addition, viral RNA was undetect-
able in the spleen of animal 350 at the time of necropsy
(though viral DNA was still present), but could be easily
isolated from splenic tissue of animal 407 or earlier
plasma from macaque 350 (Fig. 5).
Serological response to HIV-2287 challenge
To investigate the mechanism of control of viral repli-
cation in protected animals, serological reactivity of KR-
immunized animals was characterized by Western blot-
ting. Prior to challenge with HIV-2287, minimal serological
reactivity could be demonstrated. After challenge, enve-
lope reactivity actually declined in animal 407 (Fig. 6A,
lanes C and D, note loss of gp130 bands), and p26
antibody was not detectable 52 wpi (lane D), whereas
animals 292 and 350 exhibited anamnestic responses to
envelope proteins (Fig. 6B, lanes H and L, respectively).
All animals displayed detectable serological reactivity to
p26 and an initial increase in p26 antibody after HIV-2287
FIG. 1. Effect of HIV-2287 challenge on CD4
1 lymphocyte numbers. Absolute CD41 lymphocyte counts (cells mm23) of KR-experienced animals (A)
and naive animals (B) challenged with HIV-2287 are shown. Weeks postimmunization, wpi. Animal 292 (n—high KR, high 287), 350 (h—high KR, low
287), 404 (E—low KR, low 287), and 407 (F—low KR, high 287). Animal 096 (n—naive, high 287), 192 (F—naive, high 287), 147 (h—naive, low 287),
and 172 (E—naive, low 287). (A) PRE indicates CD4 lymphocyte number determinations made over the 4 months prior to challenge (time not to scale).
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inoculation (Fig. 6) consistent with an accelerated re-
sponse. The inability to detect envelope antibody in an-
imal 407 after HIV-2287 challenge (Fig. 6A, compare lanes
B and C) may be explained by the extremely high early
viremia (Fig. 4B, 1 wpi, solid bars, .108 copies ml21).
Neutralizing activity, as assessed by syncytial inhibition
on HT4-6C, could not be detected in the sera of HIV-2KR-
infected macaques either before or after challenge with
HIV-2287, while control sera from HIV-2 infected individ-
uals produced 50% inhibition at titers from 1:80 to 1:160
(not shown). Using a more sensitive constant-serum,
varying-virus p26-based neutralization assay to detect
HIV-2 replication in human PBMC, pooled serum from
SIVmac239- and SIVmac251-infected macaques exhibited
significant neutralizing activity, producing a 2 log5 reduc-
tion in the titer of HIV-2287 (Table 2, left) and a 1.25 log10
reduction in the titer of HIV-2KR (Table 2, right); however,
no significant neutralizing activity of KR-infected ma-
caque sera against either virus could be demonstrated
either before HIV-2287 challenge (0 wpi) or up to 58
weeks after HIV-2287 challenge.
CD81 cytotoxic lymphocyte activity correlates
with protection
To determine if cytotoxic lymphocyte activity was in-
volved in protection from CD4 decline, PBMC from naive
and HIV-2KR-immunized animals were exposed to two in
vitro cycles of stimulation, and bulk-stimulated popula-
tions analyzed for CTL activity. No HIV-2 gag-specific
CTL activity was detected 14 months after immunization
with either low or high doses of HIV-2KR, just before
HIV-2287 challenge (Table 3). However, in the months
following HIV-2287 challenge, specific lysis of gag-ex-
pressing BLCL targets was detected in both animals
previously exposed to high-dose HIV-2KR (292 and 350).
In contrast, specific lysis was either not detected or
FIG. 3. CD41 lymphocyte proviral burden in protected and unpro-
tected animals. Shown are log10 average proviral copies/10
6 PBMC.
Each value represents two or more determinations on two or more
samples. Error bars represent standard deviations. (A) Naive animals.
(B) HIV-2KR-immunized animals. Solid black and white bars denote
animals receiving the high inoculum of HIV-2287, and stippled and gray
bars denote animals receiving the low inoculum.
FIG. 2. Quantitative culture of PBMC. PBMC from challenged animals
were serially diluted 10-fold starting with 1 3 106 cells and cocultured
with 1 3 106 fresh PHA/IL-2 stimulated allogenic M. nemestrina PBMC.
Titers are expressed as the log of the maximal dilution yielding a
positive culture by p26 EIA of supernatant within 8 weeks. (A) Naive
animals 096, 147, 172, and 192. (B) KR-immunized animals 292, 350, 404,
and 407. Solid black and white bars denote animals receiving the high
inoculum of HIV-2287, and stippled and gray bars denote animals
receiving the low inoculum. No virus could be detected from animal 404
at 1 wpi.
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detected only at low levels (,3% specific lysis), in neg-
ative control animals (165, 296), naive animals chal-
lenged with HIV-2287 (096, 192, 368), and in animals
previously exposed to a low dose of HIV-2KR (404, 407). In
animal 292, still surviving, CTL activity was present at all
time points measured, and, in animal 350, significant
CTL activity (.4% specific lysis) was present on two of
three occasions. Both animals protected from lethal
HIV-2 disease had gag-specific CTL activity detected up
to 6 months after HIV-2287 challenge. To determine the
phenotype of effector cells responsible for the observed
CTL activity, specific lysis of HIV-2 gag-expressing BLCL
targets by positively selected CD8-enriched mononu-
clear cells was compared to that exhibited by unselected
and CD8-depleted PBMC effectors. The major effector
population responsible for in vitro activity consisted of
CD8, presumably MHC class I-restricted, cytotoxic lym-
phocytes (Fig. 7).
DISCUSSION
Inoculation with SIV viral strains of reduced pathoge-
nicity has previously been shown to prevent infection or
disease progression after challenge with pathogenic SIV
(Marthas et al., 1990; Daniel et al., 1992; Lohman et al.,
1994; Almond et al., 1995; Clements et al., 1995; Putkonen
et al., 1995, 1996; Hirsch et al., 1996; Wyand et al., 1996).
While protection from infection is elicited by attenuated
homologous clones (Daniel et al., 1992; Almond et al.,
1995) 8 months or more after immunization, protection
has been noted to be incomplete when heterologous
virus is used for challenge (Putkonen et al., 1990; Clem-
ents et al., 1995; Abimiku et al., 1995; Letvin et al., 1995;
Petry et al., 1995; Vogt et al., 1995; Wyand et al., 1996) or
when challenge is performed too early after inoculation.
Moreover, the degree of protection may be related to the
level of replication of the immunizing virus (Daniel et al.,
1992).
In this study, animals previously inoculated with 104
SFU, but not 103 SFU, of the avirulent HIV-2KR molecular
clone were protected from CD4 decline and immunode-
ficiency disease after challenge with HIV-2287 (Ho et al.,
1996). Dose dependence of protection, with regard to the
inoculum of immunizing virus, was suggested by the
difference in CD4 decline in animals immunized with the
higher and lower doses, as well as the slower CD4
decline and longer survival of ‘‘unprotected’’ HIV-2KR-ex-
perienced animals compared to naive controls. Viremia
after infection with HIV-2KR was of comparable magni-
tude and duration in all immunized animals, so that
dose-dependent protection could not be foreseen. Pro-
tection was not simply a function of the greater amount
of viral protein administered to animals 292 and 350,
however, as two macaques administered 2003 more
viral antigen in the form of a noninfectious nef-dele-
tion mutant, were not protected from CD4 decline after
HIV-2287 challenge (not shown).
In both SIV and SHIV vaccination systems, the level of
viral replication early after infection has been demon-
FIG. 5. Inability to detect viral transcripts in the spleen of protected
animal 350. Ethidium bromide-stained agarose gel of RT–PCR products
from splenic tissue from protected animal 350 and unprotected animal
407, as well as plasma RNA from animal 350 obtained 2 wpi. PCR on
each sample was performed in either the presence (1) or the absence
(2) of reverse transcription.
FIG. 4. Plasma RNA levels in protected and unprotected animals.
Values shown represent log10 of calculated RNA copies/ml plasma
using duplicate to quadruplicate samples. Columns with error bars
represent standard deviations of values obtained by three independent
RNA extraction techniques. (A) Naive animals 096, 147, 172, and 192. (B)
KR-experienced animals 292, 350, 404, and 407. Solid black or white
bars denote animals which received 105 TCID50 HIV-2287, and stippled
or gray bars denote animals receiving 101 TCID50 HIV-2287.
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strated to predict progression to disease (Letvin et al.,
1995; Hirsch et al., 1996), and in human HIV-1 infection,
viral burden has recently been shown to be a strong
predictor of outcome (Mellors et al., 1996). In this study,
administration of a low (101 TCID50) rather than high (10
5
TCID50) inoculum of HIV-2287 resulted in a 1- to 2-week
delay and a slight decline in the magnitude of maximal
viremia noted, and animals challenged with the low dose
of HIV-2287 also displayed slower rates of CD4 decline.
Protected animals exhibited lower levels of both plasma
RNA (2–4 logs) and proviral burden (1–3 logs) than un-
protected KR-experienced animals or naive animals in-
oculated in the same fashion. Though the number of
immunized macaques included in this initial trial was
limited, none of the naive animals survived longer than
24 wpi, and all the animals immunized with the higher
dose of HIV-2KR were protected. The large magnitude of
the differences in viral replication and CD4 lymphocyte
depletion between protected and unprotected animals
strongly suggests that control of viremia is causally as-
sociated with the observed difference in outcomes. The
prolonged control of viral replication in protected animals
in this trial, together with the observed absence of de-
tectable viral RNA in the spleen of the protected animal
which was euthanized, emphasizes that the eventual
outcome of protection from disease, but not from infec-
tion, may be both a reasonable and achievable goal of
vaccine protection and underscores the importance of
viral quantification to the understanding of vaccine ef-
fects.
The immunological mechanism controlling viral repli-
cation in protected animals remains unclear. While high
levels of neutralizing antibody have been noted to be
present in some long-term HIV-1 survivors (Sattentau
1996), and in macaques protected with live-attenuated
SIV (Putkonen et al., 1990; Daniel et al., 1992; Cao et al.,
1995; Clements et al., 1995; Wyand et al., 1996), no
evidence was found to indicate that neutralizing activity
was responsible for the observed protection in this study,
although anamnestic serological responses were seen
in all animals except for animal 407. It is tempting to
FIG. 6. Serological reactivity of HIV-2KR immunized animals. (A) Animal 407: Lanes A, B, and E—2, 24, and 52 wpi with HIV-2KR; lanes C and D—16
and 52 wpi with HIV-2287; lane F—HIV-2-seropositive human control; lane G—negative control. (B) Lane A—M. nemestrina-negative control; lane
B—M. nemestrina-positive control; lane C—human HIV-2-positive control; lane D—normal human serum. Lanes E–H, animal 292; lanes I–L, animal
350; lanes M–P, animal 404. Lanes E, I, and M: prior to HIV-2KR infection; lanes F, J, and N: 24 wpi HIV-2KR; lanes G, K, and O: 52 wpi HIV-2KR; lanes
H, L, and P—16 wpi HIV-2287.
TABLE 2
Neutralization Activity of Sera from HIV-2KR-Immunized
HIV-2287-Challenged Animals on PBMC
Animal serum
HIV-2287 HIV-2KR
0 wpia 58 wpi 0 wpia 18 wpi 27 wpi 58 wpi
J90292 3.50b 3.50 5.50 5.50 4.50 4.50
F90350 4.50 3.50 5.50 4.50 4.50 4.50
F90404 3.50 4.50 5.50 4.50 4.50 5.50
F90407 3.50 3.50 5.50 4.50 4.50 4.50
Negative control 3.70 6 0.40 4.75 6 0.43
Positive control 1.70 6 0.00 3.50 6 0.00
Note. Negative control, HIV-2287 or HIV-2KR virus without serum.
Positive control, pooled sera from SIV infected macaques.
a 0 wpi, time of HIV-2287 inoculation.
b All numbers shown represent the geometric mean titer in log
dilutions (log5 for HIV-2287, log10 for HIV-2KR).
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speculate that the high early viremia (Fig. 4B) in this
unprotected, immunized animal obscured or prevented
an antibody response.
Animals protected from CD4 decline generated HIV-2-
specific CD81 cytotoxic lymphocyte activity more fre-
quently and at greater levels than animals which pro-
gressed to CD4 decline and disease (Table 3), though no
bulk CTL activity was detectable prior to challenge. This
might represent an anamnestic reponse, whereby expo-
sure to the challenge virus resulted in rapid boosting of
preexisting CTL activity from below the limit of detection
to levels which controlled early virus replication. In con-
trast, the slower primary reponse in naive animals could
have allowed initial virus replication to overwhelm host
defenses. High levels of cytotoxic lymphocyte activity
have been found in long-term survivors of HIV-1 (Rinaldo
et al., 1995) and are associated with long-term suppres-
sion of SIV and HIV-2 replication in other macaque mod-
els (Reimann et al., 1994; Heeney et al., 1994; Gallimore
et al., 1995; Mellors et al., 1996; Johnson, 1996;). The
substantial CTL activity present in protected animals in
this trial strongly suggests a relationship with protection
from CD4 decline and the persistent control of viremia
observed in this model. However, CTL activity alone has
not been shown to predictably lead to protection (Letvin
et al., 1995; Hulskotte et al., 1995; Yasutomi et al., 1995) or
reduction in viral load in other studies. The recent de-
velopment of suitable vaccinia expression systems for
HIV-2287 gag should allow confirmation that the observed
activity is directed against the challenge strain in future
experiments. Alternatively, HIV-2-specific CD4 T-cell
helper activity elicited by HIV-2KR immunization might
have accelerated primary immune responses to HIV-2287.
Other immune factors, such as CD8-mediated suppres-
sion via chemokine inhibition of replication, might also
have facilitated protection. While some researchers have
found elaboration of chemokines by PHA-stimulated
CD81 lymphocytes to correlate with protection (Lehner
et al., 1996), no differences in the plasma concentration
of RANTES were noted between protected and unpro-
tected animals in this study (D. Looney and A. L. DeVico,
unpublished).
A larger trial is now under way to confirm and expand
upon these initial results to explore whether live-virus
vaccines which produce only transient infection, poten-
TABLE 3
CTL Activity of M. nemestrina after HIV-2287 Challenge
Animal
Exposure
Percent specific lysis at E:T of 25:1 after HIV-2287 exposure (months)
0 1 2 6
HIV-2KR HIV-2287 vac
a gagb vac gag vac gag vac gag
J90292 High High 2 4 1 23 2 13 0 22
F90350 High Low 0 3 1 11 0 4 0 7
F90404 Low Low 0 2 0 0 0 0 3 4
F90407 Low High 0 0 4 4 0 0 NT NT
J92096 None High 0 0 0 0 NT NT NT NT
F91368 None High NTc NT 1 1 0 0 NTd NTd
T92192 None High 0 0 0 0 2 0 NTd NTd
F92296 None None NT NT 0 2 1 0 0 0
F92165 None None 0 0 1 0 3 1 0 2
a vac, autologus BLCL infected with wild-type vaccinia virus.
b gag, autologus BLCL infected with rVV expressing HIV-2 gag.
c NT, not tested.
d Animal died of AIDS.
FIG. 7. Phenotype of CTL effectors in animal 292. Specific lysis
exhibited by unfractioned PBMC (open bar) or fractions enriched
(cross-hatched) or depleted (solid bar) of CD81 lymphocytes against
autologous BLCL infected with recombinant vaccinia expression
HIV-2KR gag. Cytolytic assays were performed using PBMC from animal
292 obtained 4 wpi at an effector:target ratio of 25:1.
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tially more acceptable for eventual human trial, might
nonetheless confer significant protection from develop-
ment of immunodeficiency disease.
MATERIALS AND METHODS
Cells
HeLa-CD4 (HT4-6C), Molt4/Clone 8 (Molt4/8), and pe-
ripheral blood mononuclear cells (PBMC) were grown in
RPMI containing 10% heat-inactivated fetal calf serum
(FCS) with 100 U/ml penicillin, 100 mg/ml streptomycin,
and 2 mM L-glutamine. PBMC were stimulated with 5
mg/ml PHA-P for 24–48 h (Sigma, St. Louis, MO) and
cultured in media containing 100 U/ml human IL-2
(Schiapparelli Biosystems, Columbia, MD).
Viruses
The immunizing viral stock was prepared from Molt4/8
cells infected with HIV-2KR (Kraus et al., 1998) and titered
on HT4-6C (Chesebro et al., 1991; Kimpton and Emmer-
man, 1992). HIV-2287 was derived by serial passage of
HIV-2EHO (Dr. Luc Montagnier, Pasteur Institute) in M.
nemestrina. Animal F87265 (265) was inoculated intrave-
nously with 106 TCID50 cell-free HIV-2EHO as well as 10
7
autologous PBMC infected in vitro. Ten milliliters of
whole blood obtained from macaque 265 at 44 wpi was
transfused into animal F89071 (071), and then 10 ml of
blood from animal 071 at 20 wpi was inoculated into
F89287 (287). The HIV-2287 challenge stock was derived
from coculture of lymph node mononuclear cells of ani-
mal 287 with fresh stimulated allogenic macaque PBMC.
Virus stocks were prepared as clarified supernatants
(3000 g for 20 min at 4°C) and aliquoted and stored at
280°C until use. HIV-2287 virus for neutralization assays
was obtained from coculture of plasma from infected
animal 192 at 1 wpi with human PBMC.
Animal immunization
Animals J90292 and F90350 (292 and 350) were inoc-
ulated with 104 SFU and macaques F90404 and F90407
(404 and 407) were immunized with 103 SFU of HIV-2KR
(Kraus et al., 1998). Challenge was performed 14 months
after immunization with HIV-2KR. Animals 292 and 407
were inoculated intravenously with 105 TCID50 HIV-2287
and animals 350 and 404 with 101 TCID50 of HIV-2287.
Naive animals J92096, T92192, F91368, and M91392 (096,
192, 368, and 392) were inoculated with 105 TCID50 and
F92147 and J92172 (147 and 172) were inoculated with
101 TCID50 of HIV-2287 (Table 1). Negative control animals
included J92165 and F92296 (165 and 296).
Analysis of lymphocyte subsets and flow cytometry
Lymphocytes purified from buffy coats of freshly col-
lected EDTA anticoagulated whole blood were stained to
enumerate T-cell subsets using FITC-conjugated anti-
CD4 (Leu 3a) and phycoerythrin-conjugated anti-CD8
(Leu 2a) monoclonal antibodies according to the manu-
facturer’s directions (Becton–Dickinson, Mountain View,
CA) for flow cytometric analysis (Coulter).
DNA and RNA extraction
PBMC were isolated by 93% Ficoll–Paque (Pharmacia)
gradient centrifugation of blood diluted 1:1 with Hanks’
balanced salt solution (HBSS). DNA from PBMC (3–10 3
106) was extracted using QIAamp columns (QIAGEN)
according to the manufacturer’s instructions. For viral
RNA, acid–citrate–dextrose anticoagulated plasma
(400 ml to 4 ml) was ultracentrifuged (100,000 g, 1 h, 4°C),
pellets were lysed in 200 ml RNAzol (Tel-Test Inc., Friend-
swood, TX), and RNA was isolated according to the
manufacturer’s directions. For quantitation, RNA was re-
suspended in 10–40 ml diethylpyrocarbonate (DEPC)-
treated H2O.
Quantitative culture
Lymphocytes were serially diluted 1:10 in duplicate,
starting with 106 cells, into 24-well tissue culture plates
containing 106 allogenic PHA/IL-2 stimulated M. nemes-
trina PBMC. Wells were sampled weekly and fed with
fresh cells as needed, and p26 antigen was determined
by Coulter SIV Antigen Capture EIA. Cultures were con-
sidered positive if the supernatant p26 exceeded back-
ground by threefold. Titers were calculated as the geo-
metric mean of the maximal dilution of cells which gave
positive cultures.
Quantitative PCR
Quantitative competitive PCR (QC–PCR) was per-
formed on aliquots of genomic DNA or 10-ml volumes of
RNA, diluted so that equivalence occurred between 103
and 105 copies of QC template. QC template was pro-
duced by cloning a 51-bp synthetic sequence into a
SpeI–SmaI deletion in the wild-type PCR product in pBS-
KS2. RNA was transcribed using SP6 RNA polymerase
(Riboprobe kit, Promega). Template RNA (101–106 copies)
was added to 100 pmol of downstream primer 126 (59-
CAA-AGC-CAA-TTG-GTG-TTA-TC-39) in a final volume of
14.2 ml, denatured at 68°C for 8 min, chilled on ice, and
added to reverse transcriptase mix (25 mM Tris–HCl, pH
8.3, 50 mM KCl, 2 mM MgCl2, 100 mg/ml BSA, 1 mM
dNTP, 10 mM DTT) and 200 U of M-MLV reverse tran-
scriptase (GIBCO-BRL, Life Technologies) in a final vol-
ume of 20 ml. Reverse transcription (37°C, 45 min) was
followed by 2 min at 90°C and 2 min at 4°C. For QC–PCR
of viral DNA, QC template DNA was added directly to
100- to 500-ng samples of genomic DNA in 20 ml H2O.
For PCR, 20-ml samples were added to 100 ml PCR
reaction mix containing 1.5 mM MgCl2, 50 mM KCl, 10
mM Tris–HCl, pH 8.3, 200 mM each dNTP, 7 mM digoxi-
genin-11–dUTP, 1 mM each of primer 124 (59-AGT-CTC-
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ATA-GCC-AAC-ATT-GA-39) and primer 126, and 2.5 U of
Taq DNA polymerase (Boehringer Mannheim). Samples
were denatured at 94°C for 45 s, followed by 35 cycles of
94°C for 30 s, 59°C for 30 s, 72°C for 60 s, and final
extension for 7 min at 72°C.
EIA was performed in duplicate on each sample. Re-
action products (20 ml) were mixed with 50 ml of 23
hybridization solution (123 SSC, 10 mM Tris–HCl, pH 7.5,
10 mM EDTA) and 30 ml of 50 nM 39-biotinylated capture
probe (wild-type probe env144: 59-AGT-GCA-GAA-GTG-
TCA-GAA-CTG-TAT-AAA-TTG-GA-39 or QC probe env145:
59-TGG-GCT-ACG-TCT-TGC-TGG-CGT-TCG-CGA-CGC-
GA-39). Samples were denatured (95°C, 5 min), cooled
on ice (1 min), and hybridized (20°C, 45 min). Streptavi-
din-coated plates (Pierce, Rockford, IL) were washed
three times with buffer A (100 mM Tris–HCl, pH 7.5, 150
mM NaCl, 0.05% Tween 20), incubated with blocking
solution (0.05% casein and 100 mg/ml salmon sperm
DNA in buffer A, 45 min, 20°C), and washed 33. Aliquots
of the hybridization reaction (50 ml) were incubated in
duplicate wells (20°C, 1 h), wells washed 33, 50 ml
anti-digoxigenin alkaline phosphatase conjugate (1:750
dilution, buffer A) added, and plates incubated (37°C,45
min). Substrate (100 ml, 3.8 mM p-nitrophenyl phosphate,
0.5 mM MgCl2, 87 ml diethanolamine, pH 9.5) was added
to each well, and absorbance read at 405 nM (605 nM
background) at 30-min intervals. Controls included M.
nemestrina genomic DNA, standard curves of WT and
QC plasmid, and titrated WT plasmid with constant QC
plasmid copies.
Qualitative RT–PCR from spleen viral RNA
RNA was extracted from the spleen of macaques 350
and 407. After mincing, tissue was dissolved in RNAzol,
and RNA obtained as described above. Samples were
reverse-transcribed (Access RT–PCR, Promega) and am-
plified (35 cycles, 94°C 58°C) with 59 primer 290 (59-CAA-
TAA-AAC-CAT-GTG-TTA-AAT-TAA-CC-39) and 39 primer
244 (59-GCA-CAA-TAC-CTA-AAT-CTT-AAA-CTA-TCC-39),
according to the manufacturer’s directions.
Western blot analysis
Sera were heat-inactivated at 56°C for 30 min before
incubation with Western blot strips. Strips were prepared
using 2003 concentrated HIV-2KR virus (100,000 g, 1 h)
grown in Molt4/8 cells. Pelleted virus was lysed in sam-
ple buffer (65 mM Tris–HCl, 2% SDS, 10% glycerol, 0.01%
bromphenol blue, 4% 2-b-mercaptoethanol, pH 8.0), run
on 12% polyacrylamide gels, and transferred to PVDF
membranes (Immobilon) at 200 mA overnight in a Hoefer
semidry blotting apparatus. Strips were blocked (5%
powdered milk, 0.1% Tween 20, and 5% horse serum, 100
mM Tris, 1 h), incubated with sera (1:50 in PBS) overnight
at 4°C, and washed 33 (PBS with 0.05% Tween 20), and
protein bands developed using protein G horseradish
peroxidase conjugate (1:5000) and diaminobenzidine
substrate solution (Sigma).
Virus neutralization
Virus neutralization was performed as previously de-
scribed by syncytial focus assay using HT4-6C cells (Ho
et al., 1996) and by reduction of titer on PBMC. Neutral-
ization assays on PBMC were performed by diluting virus
serially (1:5 or 1:10 in duplicate) for each test serum in
U-bottomed microtiter wells and adding a fixed 1:40 final
dilution of each serum to each well. Neutralization activ-
ity against both HIV-2KR and HIV-2287 was determined in
separate experiments. Sera of challenged animals 292,
350, 404, and 407, at 0, 18, 27, and 58 wpi for HIV-2KR and
0 and 58 wpi for HIV-2287, were used. Virus/sera mixtures
were incubated for 45 min at 4°C and 45 min at 37°C,
and then 5 3 105 PHA/IL-2 treated PBMC were added to
each well. Cells were infected for 3 h at 37°C, washed
33 with PBS, and incubated in RPMI medium containing
100 U/ml IL-2. Endpoints were determined by p26 anti-
gen capture assay of culture well supernatants on day 8
for HIV-2KR and on day 10 for HIV-2287. Titration of virus
alone, and in the presence of neutralizing positive control
sera (pooled sera from SIVmac239- and SIVmac251-infected
macaques, courtesy P. Johnson) were included. Results
are reported as the virus titer in the presence or the
absence of sera, expressed as the geometric mean log
dilution which was positive.
Recombinant vaccinia virus
A KpnI–EcoRI fragment of pEPG containing a portion of
the leader sequence and the complete gag coding re-
gion (HIV-2SBL-ISY nucleotides 421–2653) was blunt-
ended and cloned into the SmaI site of the vaccinia
insertion vector pVV1 (Weir et al., 1982) just downstream
of the vaccinia growth factor promoter (VGFP) and in-
serted between the viral thymidine kinase sequences, to
create pVV-ISY gag. The pVV-ISY gag vector was trans-
fected into human TK2 143B cells previously infected
with VV-WR wild-type vaccinia virus. Recombinant vac-
cinia virus expressing HIV-2 gag (VVgag) was obtained
as described (Panicali and Paoletti, 1982; Mackett et al.,
1984) by three cycles of plaque purification of BUdR-
resistant TK2 viral clones screened for gag sequences
using a 32P-labeled pEPG probe (Steffy et al., 1992). Viral
stocks were grown on HeLa cells and stored at 280°C
until use.
Target cell lines
Autologous B-lymphoblastoid cells lines (BLCL) were
established by infecting 105 PBMC in 100 ml of R15 (RPMI
medium with 15% FCS) with 100 ml supernatant from
S394-1X1055 cells producing Herpesvirus papio (gift of
Dr. Sharp, Southwest Foundation for Biomedical Re-
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search) in 96-well U-bottomed microtiter plates (Costar,
Cambridge, MA). BLCL were expanded, but not cloned.
Generation of CTL lines
CTL effectors were generated in vitro by two, weekly,
sequential stimulation cycles by modification of previ-
ously described methods (Kent et al., 1995). Stimulator
cells were prepared using autologous BLCL, infected
with VV gag (m.o.i. 10, 16 h), exposed to UV light (10 min
at 4 cm distance) and g-irradiation (8000 rad), and added
to lymphocytes (10 responder:1 stimulator). Autologous
PBMC filler cells were added (1 responder:1 filler) to
cultures during the second stimulation. Each well, con-
taining 106 responder cells/ml in R15 medium, was
pulsed 48 h following stimulation with 10 U/ml of rIL-2
(Hoffman–LaRoche, Nutley, NJ).
Cytolytic activity assay
Cytolytic activity was measured in a standard 4-h 51Cr
release assay as previously described (Kent et al., 1995,
1996). Autologous BLCL target cells (1.0 3 106) infected
with VVgag were labeled (0.1 mCi Na51CrO4, NEN Prod-
ucts, Boston, MA) in 1 ml of medium and plated at 5 3
103 targets/well. Effector cells were added to targets at
varying E:T ratios (total volume 200 ml) and incubated for
4 h at 37°C. The percent specific release was calculated
by standard formula. Standard deviation of triplicate
wells was always less than 10% and spontaneous re-
lease was always less than 25% of the maximal release.
Phenotype of CTL effectors
To determine the phenotype of cells mediating cyto-
lytic responses, CD8 lymphocytes were depleted by ad-
sorption to antibody coated flasks (A.I.S., Menlo Park,
CA) according to the manufacturer’s directions (Kent et
al., 1995, 1996). Nonadherent (CD8 depleted) cells were
aspirated and adherent (CD8 enriched) cells gently re-
moved. Staining with phycoerythrin-conjugated Leu 2a
(Becton–Dickinson, Mountain View, CA) confirmed that
the CD8-enriched population contained .94% and the
CD8-depleted population ,6% CD81 T cells.
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